Start up of clinical phase III study with Lu AA21004 in Japan

Lundbeck, 05/16/2011

H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) today announced the initiation of a phase III clinical trial in Japan for Lu AA21004 in patients with major depressive disorder (MDD).

Print Article Summary Cat 2 CME Report